Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The gradual reduction of plasma testosterone in middle‐aged and older men from mid‐life onwards coincides paradoxically with the time when there is progressive growth of the prostate, a highly androgen‐dependent organ. The growing interest in androgen therapy for older men makes it essential to understand the effects of exogenous testosterone on the non‐diseased prostate, yet few studies are available. The present study examined prostate volume, prostate‐specific antigen (PSA) and lower urinary tract symptom (IPSS) score in 207 men, aged 40–83 years, presenting with clinical features of age‐related androgen deficiency [sexual and/or urinary dysfunction, elevated lutenizing hormone (LH)] who were treated for 6 months with oral testosterone undecanoate (TU). Men were divided into two groups, group 1 (n=92, plasma testosterone levels > 13 nmol/L) were treated with 80 mg daily; group 2 (n=115, plasma testosterone levels < 13 nmol/L) were treated with given 120 mg daily. Before treatment and after 1, 3 and 6 months of treatment, prostate volume was measured by ultrasound and hormones [testosterone, dihydrotestosterone, oestradiol, LH, follicle‐stimulating hormone (FSH)] and PSA were measured. Within 1 month of treatment, the elevated blood LH levels were markedly decreased in all men in group 1, as well as most men in group 2. Group 2 was subdivided into men whose LH levels were suppressed (n=95, group 2a) and those whose LH levels did not suppress (n=20, group 2b). Men in group 1 and 2a had marked decreases in prostate volume, PSA and lower urinary tract symptom (IPSS) scores whereas no significant changes were observed in group 2b. Groups 1 and 2a also had more striking suppression of LH, FSH, dihydrotestosterone and oestradiol whereas group 2b had no significant increases in blood testosterone concentrations. These findings suggest that exogenous testosterone in middle‐aged and older men with some clinical features of age‐related androgen deficiency can retard or reverse prostate growth and that elevated plasma LH may be a useful index of severity of age‐related androgen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Nieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Wayne Meikle, A., Arver, S., Dobs, A. S., Adolfsson, J., Sanders, S. W., Middleton, R. G., Stephenson, R. A., Hoover, D. R., Rajaram, L., & Mazer, N. A. (1997) · Urology · doi:10.1016/s0090-4295(96)00445-1 · Cited by 125 · cited 1×
“Previous studies of the effects of exogenous testosterone on prostate size and PSA concentrations are mostly limited to hypogonadal men (Canale et al., 1990; Sasagawa et al., 1990; Behre et al., 1994; Meikle et al., 1997; Ozata et al., 1997; Snyder et al., 2000; Jin et al., 2001).”
BackgroundUYANIK, B. S., ARI, Z., GÜMÜS, B., YIGITOGLU, M. R., & ARSLAN, T. (1997) · Japanese Heart Journal · doi:10.1536/ihj.38.73 · Cited by 75
Cited by
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182
Kalinchenko, S. Y., Kozlov, G. I., Gontcharov, N. P., & Katsiya, G. V. (2003) · The Aging Male · doi:10.1080/tam.6.2.94.99 · Cited by 173
Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168
Metadata
- Authors
- Pechersky, A. V., Mazurov, V. I., Semiglazov, V. F., Karpischenko, A. I., Mikhailichenko, V. V., & Udintsev, A. V.
- Venue
- International Journal of Andrology
- Publisher
- Wiley
- Published
- 2002-03-18
- Volume
- 25
- Issue
- 2
- Pages
- 119-125
- ISSN
- 0105-6263 (ISSN-L)
- 1365-2605
- OpenAlex
- W2136495987
- Cited by
- 50
- References
- 6
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. https://app.cochat.ai/papers/10.1046/j.1365-2605.2002.00335.x
- The paper
- Pechersky, A. V., Mazurov, V. I., Semiglazov, V. F., Karpischenko, A. I., Mikhailichenko, V. V., & Udintsev, A. V. (2002). Androgen administration in middle‐aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. International Journal of Andrology. https://doi.org/10.1046/j.1365-2605.2002.00335.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.